252 related articles for article (PubMed ID: 24570392)
21. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
Li X; Liu X; Zhang L; Li C; Zhang E; Ma W; Fan Q; Yu JJ
Oncotarget; 2017 May; 8(22):36628-36638. PubMed ID: 28410230
[TBL] [Abstract][Full Text] [Related]
22. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
23. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.
Fujita A; Ando K; Kobayashi E; Mitani K; Okudera K; Nakashima M; Miyatake S; Tsurusaki Y; Saitsu H; Seyama K; Miyake N; Matsumoto N
Hum Genet; 2016 Jan; 135(1):61-8. PubMed ID: 26563443
[TBL] [Abstract][Full Text] [Related]
24. Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis.
Ando K; Fujino N; Mitani K; Ota C; Okada Y; Kondo T; Mizobuchi T; Kurihara M; Suzuki K; Hoshika Y; Ebana H; Kobayashi E; Takahashi K; Kubo H; Seyama K
Am J Physiol Lung Cell Mol Physiol; 2016 May; 310(10):L899-908. PubMed ID: 27016587
[TBL] [Abstract][Full Text] [Related]
25. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis.
Sato T; Seyama K; Kumasaka T; Fujii H; Setoguchi Y; Shirai T; Tomino Y; Hino O; Fukuchi Y
J Intern Med; 2004 Aug; 256(2):166-73. PubMed ID: 15257730
[TBL] [Abstract][Full Text] [Related]
26. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene.
Maruyama H; Seyama K; Sobajima J; Kitamura K; Sobajima T; Fukuda T; Hamada K; Tsutsumi M; Hino O; Konishi Y
Mod Pathol; 2001 Jun; 14(6):609-14. PubMed ID: 11406664
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis.
Evans SE; Colby TV; Ryu JH; Limper AH
Chest; 2004 Mar; 125(3):1063-70. PubMed ID: 15006970
[TBL] [Abstract][Full Text] [Related]
28. Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
Babaei-Jadidi R; Dongre A; Miller S; Castellanos Uribe M; Stewart ID; Thompson ZM; Nateri AS; Bradding P; May ST; Clements D; Johnson SR
Am J Respir Crit Care Med; 2021 Aug; 204(4):431-444. PubMed ID: 33882264
[No Abstract] [Full Text] [Related]
29. Lymphangioleiomyomatosis and tuberous sclerosis complex.
Chorianopoulos D; Stratakos G
Lung; 2008; 186(4):197-207. PubMed ID: 18408969
[TBL] [Abstract][Full Text] [Related]
30. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
31. [Pulmonary lymphangioleiomyomatosis. Morphologic and immunohistochemical findings].
Kuhnen C; Preisler K; Müller KM
Pathologe; 2001 May; 22(3):197-204. PubMed ID: 11402850
[TBL] [Abstract][Full Text] [Related]
32. Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.
Lesma E; Chiaramonte E; Ancona S; Orpianesi E; Di Giulio AM; Gorio A
Biomed Res Int; 2015; 2015():315240. PubMed ID: 25699271
[TBL] [Abstract][Full Text] [Related]
33. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene.
Pacheco-Rodriguez G; Kumaki F; Steagall WK; Zhang Y; Ikeda Y; Lin JP; Billings EM; Moss J
J Immunol; 2009 Feb; 182(3):1270-7. PubMed ID: 19155472
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.
Ikeda Y; Taveira-DaSilva AM; Pacheco-Rodriguez G; Steagall WK; El-Chemaly S; Gochuico BR; May RM; Hathaway OM; Li S; Wang JA; Darling TN; Stylianou M; Moss J
Am J Physiol Lung Cell Mol Physiol; 2011 Jan; 300(1):L64-72. PubMed ID: 21036916
[TBL] [Abstract][Full Text] [Related]
35. Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Guo CJ; Abramova E; Golden TN; Sims M; James ML; Beers MF; Gow AJ; Krymskaya VP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):96-104. PubMed ID: 25474372
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis.
Astrinidis A; Khare L; Carsillo T; Smolarek T; Au KS; Northrup H; Henske EP
J Med Genet; 2000 Jan; 37(1):55-7. PubMed ID: 10633137
[TBL] [Abstract][Full Text] [Related]
37. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
38. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
Kristof AS; You Z; Han YS; Giaid A
Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Maisel K; Merrilees MJ; Atochina-Vasserman EN; Lian L; Obraztsova K; Rue R; Vasserman AN; Zuo N; Angel LF; Gow AJ; Kang I; Wight TN; Eruslanov E; Swartz MA; Krymskaya VP
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):723-732. PubMed ID: 30095976
[TBL] [Abstract][Full Text] [Related]
40. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.
Ferrans VJ; Yu ZX; Nelson WK; Valencia JC; Tatsuguchi A; Avila NA; Riemenschn W; Matsui K; Travis WD; Moss J
J Nippon Med Sch; 2000 Oct; 67(5):311-29. PubMed ID: 11031360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
